top of page

About NEDA

Ethics governing NEDA research

The NEDA project has undergone extensive ethical review throughout each state and territory of  Australia, and by the University of Notre Dame Human Research and Ethics Committee. The project has been approved by the lead ethics committee at the Royal Prince Alfred Hospital in Sydney, overseeing all Public Institutions operating under the National Mutual Agreement in NSW, QLD, VIC, SA and ACT.

​

Public Institutions not operating under the National Mutual Agreement will need to seek individual ethics approval as required by their institution. Private practices are covered either by the University of Notre Dame HREC or under their own local HREC and governance arrangements.

​

Approval to obtain linkage with the National Deaths Index has been approved by the Australian Institute for Health and Welfare (AIHW) Human Research and Ethics Committee. All research is governed by appropriate guidelines and the NHMRC statement on ethical conduct of human research.

Principal Investigators

david-playford.png

Professor David Playford

Director and Chief Investigator

Professor David Playford is the Professor of Cardiology at the University of Notre Dame, Fremantle, Australia where he was awarded the Vice Chancellor’s Award for Teaching Excellence, and coordinates the undergraduate cardiovascular teaching program.

​

He is a regular invited speaker to National and International conferences where his research has attracted significant international attention.

​

David is a Consultant Cardiologist specialising in Cardiac Imaging, having run a specialist echo laboratory, an echo core lab, and an advanced echo fellowship program. His clinical practice is now at Genesis Care where his interests are Cardiac Risk Assessment, Breathlessness and Pulmonary Hypertension, Heart Failure, Valvular Heart Disease and CardioOncology.

​

As a researcher of international reputation, he is Principal Investigator of the National Echo Database Australia (NEDA), the largest mortality-linked echo database in the world, and has a number of highly cited publications.

​

His Artificial Intelligence program focuses on automation of interpretation of Echo and ECG data. Awards for the AI work include the WA Startup Innovation of the Year award 2019 and the EchoVation Challenge competition in USA in 2018.

geoff-strange.png

Professor Geoff Strange

Director and Chief Investigator

PHD FCSANZ FPHSANZ

Professor Geoff Strange is creator, Director and Chief Investigator of the National Echo Database of Australia and New Zealand.

 

Geoff is a Professor within the School of Medicine at the University of Notre Dame Australia and a Fellow of the Cardiac Society of Australia and New Zealand. 

 

He is a member of the cardiology research team at Royal Prince Alfred Hospital in Sydney and he is also the current and founding CEO of the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) for which he is also Chief Investigator of the PHSANZ Pulmonary Hypertension Registry.

 

Geoff’s research interests include: Big Data for Cardiovascular Disease (Aortic Stenosis), Pulmonary Hypertension, Congenital Heart Disease and Echocardiography. Geoff has established the Congenital Heart Alliance of Australia and New Zealand, a research entity spanning fifteen centres across the region (initiating 27 M in funding for the National Action Plan on childhood heart disease from The Hon Minister Hunt). Geoff has over 70 peer reviewed publications and scientific abstracts, including various books and book chapters. He is a reviewer of the Journals, JACC, JASE, BMJ, Pulmonary Circulation and Heart, Lung and Circulation. Alongside his academic career and achievements Geoff has eighteen years of senior leadership experience operating at Vice President level in big pharma, bio-tech start-ups and device manufacturers. Geoff specialises in taking scientific and clinical data / concepts, through to commercial success. 

 

Geoff is the Director and owner of Mozaic Solutions, a consulting company set up to meet industry needs from strategic medical marketing, marketing, medical writing, scientific protocol development and trial implementation, advisory and KOL management.

Steering Committee Members

  • Professor David Celermajer

  • Professor Greg Scalia

  • Professor Tom Marwick

  • Associate Professor David Prior

  • Dr Majo Joseph

  • Dr Marcus Ilton

  • Professor Simon Stewart

  • Professor Jim Codde

bottom of page